Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:BUXNYSE:CRLOTCMKTS:SMMNY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$157.12-0.2%$140.70$91.86▼$254.15$7.72B1.491.03 million shs247,085 shsSMMNYSiemens Healthineers$27.48-1.3%$26.86$23.28▼$30.19N/AN/A140,969 shs15,181 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International0.00%+4.81%+9.63%+14.73%-21.99%SMMNYSiemens Healthineers0.00%+0.44%+4.67%+14.14%-4.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International4.0422 of 5 stars2.12.00.04.72.22.51.9SMMNYSiemens HealthineersN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 2.19Hold$171.859.37% UpsideSMMNYSiemens Healthineers 3.50Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest SMMNY, BUX, BD1, and CRL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $182.005/16/2025SMMNYSiemens HealthineersDZ BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/14/2025CRLCharles River Laboratories InternationalCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy5/14/2025CRLCharles River Laboratories InternationalTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$179.005/8/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.005/8/2025CRLCharles River Laboratories InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.005/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$170.004/25/2025SMMNYSiemens HealthineersHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy4/25/2025SMMNYSiemens HealthineersHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/10/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$160.00 ➝ $145.004/9/2025CRLCharles River Laboratories InternationalMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$175.00 ➝ $155.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.05B1.91$21.70 per share7.24$67.80 per share2.32SMMNYSiemens HealthineersN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBUXBiomark DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$22.20M-$0.65N/A14.285.32-0.66%15.19%6.93%8/6/2025 (Estimated)SMMNYSiemens HealthineersN/AN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)Latest SMMNY, BUX, BD1, and CRL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025N/ASMMNYSiemens Healthineers$0.3548N/AN/AN/A$6.45 billionN/A5/7/2025Q1 2025CRLCharles River Laboratories International$2.06$2.34+$0.28$0.50$942.34 million$984.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/ASMMNYSiemens Healthineers$0.291.06%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.781.431.16SMMNYSiemens HealthineersN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%SMMNYSiemens HealthineersN/AInsider OwnershipCompanyInsider OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%SMMNYSiemens HealthineersN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International20,10049.12 million48.48 millionOptionableSMMNYSiemens Healthineers71,000N/AN/ANot OptionableSMMNY, BUX, BD1, and CRL HeadlinesRecent News About These CompaniesSMMNY Siemens Healthineers AG - Seeking AlphaJuly 2 at 7:24 PM | seekingalpha.comSMMNY - Siemens Healthineers AG ADR Valuation - MorningstarJune 28, 2025 | morningstar.comMSiemens Healthineers AG (SMMNY) - Yahoo FinanceJune 27, 2025 | au.finance.yahoo.comEQS-CMS: Siemens Healthineers AG: Release of a capital market informationJune 11, 2025 | markets.businessinsider.comSiemens to relocate Varian imaging system manufacturing to USMay 15, 2025 | beckershospitalreview.comBSiemens Healthineers to move some Varian manufacturing to CaliforniaMay 14, 2025 | fiercebiotech.comFSiemens Healthineers AG (ETR:SHL) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 11, 2025 | finance.yahoo.comSiemens Healthineers Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 10, 2025 | finance.yahoo.comSiemens Healthineers lowers earnings forecast on expected tariff hitMay 8, 2025 | medtechdive.comMSiemens Healthineers reports higher pay for some executives, lower pay for othersMay 8, 2025 | medicaldesignandoutsourcing.comMHealthineers: Reviewing Q2 And Updating My Targets (Rating Upgrade)May 8, 2025 | seekingalpha.comSiemens Healthineers AG (SMMNY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...May 8, 2025 | finance.yahoo.comSiemens Healthineers sees up to $340 million tariff hit in second half of 2025May 7, 2025 | msn.comStrong Imaging Performance and Strategic Management Drive Positive Outlook for Siemens Healthineers AGMay 7, 2025 | tipranks.comSiemens Healthineers Posts Profit, Revenue Rise; Adjusts Guidance on Tariff UncertaintyMay 7, 2025 | wsj.comSiemens Healthineers posts revenue beat, but lowers floor of profit outlookMay 7, 2025 | reuters.comCardiovascular Image Fusion Software Market Analysis Report, 2025-2035, Featuring Ziehm Imaging, TeraRecon, OsiriX, Materialise, Siemens Healthineers and MoreMay 5, 2025 | globenewswire.comMore Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 2025May 1, 2025 | businesswire.comEQS-CMS: Siemens Healthineers AG: Release of a capital market informationApril 28, 2025 | markets.businessinsider.comSiemens Healthineers and Tower Health partner to enhance medical equipmentApril 4, 2025 | medicaldevice-network.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeStarbucks Stock: Culture Fix May Be Key to Long-Term GrowthBy Chris Markoch | June 12, 2025View Starbucks Stock: Culture Fix May Be Key to Long-Term GrowthSMMNY, BUX, BD1, and CRL Company DescriptionsBiomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$157.12 -0.37 (-0.23%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$157.12 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Siemens Healthineers OTCMKTS:SMMNY$27.48 -0.37 (-1.31%) As of 07/3/2025 12:53 PM EasternSiemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. Its Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, solutions, and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services, and digital solutions and applications for managing treatment and therapy. Its Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms. It offers essential technical customer service, such as maintenance and repair; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as digital healthhcare consulting, products, and services. The company is headquartered in Forchheim, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
